- Recursion (RXRX, Financial) reports a promising 43% reduction in polyp burden in its Phase 1b/2 TUPELO trial.
- Analysts project a significant potential upside for RXRX stock, estimating a one-year target price of $8.50.
- RXRX holds a "Hold" status with an average brokerage recommendation of 2.8.
Recursion Pharmaceuticals Inc. (RXRX) is making headlines with their recent release of preliminary results from the Phase 1b/2 TUPELO trial. This study spotlighted REC-4881, which could be a groundbreaking treatment for Familial Adenomatous Polyposis (FAP). The results are compelling, showing a median 43% reduction in polyp burden among patients after just 13 weeks. REC-4881 has already caught the attention of the Food and Drug Administration (FDA), earning both Fast Track and Orphan Drug designations, underscoring its potential in addressing unmet medical needs.
Wall Street Analysts' Projections
Wall Street is taking note of Recursion's progress. Six financial analysts have set a one-year average target price for RXRX at $8.50. Their projections range from a high of $11.00 to a low of $6.00. This average target suggests a remarkable upside potential of 49.12% from the current trading price of $5.70. Investors seeking further insights into these estimates can access more detailed information on the Recursion Pharmaceuticals Inc (RXRX, Financial) Forecast page.
The broader consensus among eight brokerage firms places Recursion Pharmaceuticals Inc. with an average brokerage recommendation of 2.8, which classifies the stock as a "Hold." This rating is derived from a scale of 1 to 5, where 1 indicates a "Strong Buy" and 5 represents a "Sell."
Long-Term Value Projections
Taking into account GuruFocus's proprietary metrics, the estimated GF Value for Recursion Pharmaceuticals Inc. in the next year is $13.21. This figure implies a staggering upside of 131.75% from the current price of $5.70. The GF Value metric reflects GuruFocus's assessment of the stock's fair trading value, considering historical trading multiples, business growth patterns, and anticipated future performance. Investor-centric data and additional metrics are available on the Recursion Pharmaceuticals Inc (RXRX, Financial) Summary page.
